{
    "id": 3645,
    "fullName": "FGFR2 K310R",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 K310R lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). K310R has not been biochemically characterized, however, is not transforming in cell culture (PMID: 18552176) and therefore, is predicted to have no effect on Fgfr2 protein function.",
            "references": [
                {
                    "id": 252,
                    "pubMedId": 18552176,
                    "title": "Drug-sensitive FGFR2 mutations in endometrial carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18552176"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "K310R",
    "createDate": "03/10/2015",
    "updateDate": "10/02/2018",
    "referenceTranscriptCoordinates": {
        "id": 90128,
        "transcript": "NM_000141",
        "gDna": "chr10:g.121519989T>C",
        "cDna": "c.929A>G",
        "protein": "p.K310R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 17132,
                "profileName": "FGFR2 K310R FGFR2 N549K"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4057,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).",
            "molecularProfile": {
                "id": 17132,
                "profileName": "FGFR2 K310R FGFR2 N549K"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4388,
                    "pubMedId": 25169980,
                    "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25169980"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8473,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 17132,
                "profileName": "FGFR2 K310R FGFR2 N549K"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520).",
            "molecularProfile": {
                "id": 17132,
                "profileName": "FGFR2 K310R FGFR2 N549K"
            },
            "therapy": {
                "id": 2507,
                "therapyName": "FIIN-1",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2410,
                    "pubMedId": 20338520,
                    "title": "A structure-guided approach to creating covalent FGFR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20338520"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8487,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 17132,
                "profileName": "FGFR2 K310R FGFR2 N549K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 2871,
                "name": "endometrial carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8851,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",
            "molecularProfile": {
                "id": 26470,
                "profileName": "FGFR2 K310R FGFR2 N550K"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6769,
                    "pubMedId": 26294741,
                    "title": "Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26294741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10770,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and induced cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 5612,
                "therapyName": "BGJ398 + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 1293,
                "therapyName": "Alpelisib + BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 K310R and N550K, PIK3R1 R557_K561delinsQ, and PTEN R130fs in culture, and tumor regression in xenograft models (PMID: 28119489).",
            "molecularProfile": {
                "id": 27769,
                "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs"
            },
            "therapy": {
                "id": 5613,
                "therapyName": "BGJ398 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8811,
                    "pubMedId": 28119489,
                    "title": "PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28119489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3446,
            "profileName": "FGFR2 K310R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17132,
            "profileName": "FGFR2 K310R FGFR2 N549K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26470,
            "profileName": "FGFR2 K310R FGFR2 N550K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27769,
            "profileName": "FGFR2 K310R FGFR2 N550K PIK3R1 R557_K561delinsQ PTEN R130fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 90132,
            "transcript": "XM_006717712",
            "gDna": "chr10:g.121515190T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90131,
            "transcript": "XM_017015924",
            "gDna": "chr10:g.121515187T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90133,
            "transcript": "NM_001144913",
            "gDna": "chr10:g.121519989T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90126,
            "transcript": "NM_001144917",
            "gDna": "chr10:g.121519989T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90130,
            "transcript": "XM_017015925",
            "gDna": "chr10:g.121515187T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90127,
            "transcript": "NM_001320658",
            "gDna": "chr10:g.121519989T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90129,
            "transcript": "NM_022970",
            "gDna": "chr10:g.121519989T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 90128,
            "transcript": "NM_000141",
            "gDna": "chr10:g.121519989T>C",
            "cDna": "c.929A>G",
            "protein": "p.K310R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}